SER-262
SER-262-001
Phase 1 small_molecule completed
Quick answer
SER-262 for Clostridium Difficile Infection is a Phase 1 program (small_molecule) at Seres Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Seres Therapeutics
- Indication
- Clostridium Difficile Infection
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed